Isomorphic Labs, a Google DeepMind spinoff, plans to begin testing its first AI-designed drugs this year, as technology startups rush to transform algorithmic magic into real medical treatments. CEO, Demis Hassabis, stated at the World Economic Forum that the firm hopes to have drugs in clinical trials by the end of the year. AI-powered drug discovery has great potential, offering faster development, reduced costs, and new cures. Over 460 AI startups are currently working on drug discovery, with over a quarter based in Europe. The global investment in this area exceeds $60 billion, and the flow of funding shows no signs of stopping. Despite the enthusiasm for discovering drugs through AI, the ultimate impact will depend on the decisions of big pharmaceutical companies to manufacture, market, and distribute these drugs.
Exciting collaborations between pharma giants and AI startups are already in progress. Isomorphic Labs has signed lucrative deals with Eli Lilly and Novartis for AI-based research into therapeutics. The company is working on real drug programs and expects to have AI-designed drugs in the clinic in the next few years. Other companies, such as Exscientia and Recursion, are also making strides in AI-driven drug discovery and market consolidation. However, there are many early-stage companies focusing on niche applications of AI technology, such as CardiaTec and Multiomic Health, which are working on drugs to treat specific medical conditions. Although AI can accelerate the discovery of compounds for new drugs, it won’t eliminate the time-consuming steps involved in drug development. Nevertheless, AI’s true potential lies in identifying targets that may have been overlooked, saving researchers time and unlocking new treatments.
The ainewsarticles.com article you just read is a brief synopsis; the original article can be found here: Read the Full Article…
